Physician profile
Gary Ruoff
NPI 1316908585
$11,721.61
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,845 · 2020: $6,976 · 2022: $900.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $10,303.27 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $900.00 | 2022 | |
| Novo Nordisk INC | $175.17 | 2019 | |
| Lilly USA, LLC | $143.90 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $117.06 | 2019 | |
| Janssen Pharmaceuticals, INC | $27.96 | 2019 | |
| Amgen INC. | $26.85 | 2019 | |
| Shire North American Group INC | $15.39 | 2019 | |
| Supernus Pharmaceuticals, INC. | $12.01 | 2019 |
3 companies reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Ruoff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.